{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-072598","form_type":"8-K/A","ticker":"CTOR","cik":"0001851484","company_name":"CITIUS ONCOLOGY, INC.","filed_at":"2024-08-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.919528+00:00","generated_at":"2026-05-31T07:43:17.056378+00:00","sec_items":["2.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"SpinCo reports $14.3M net loss for nine months; going concern uncertainty raised","bullets":["Net loss of $14.3M for nine months ended June 30, 2024 (vs $7.5M prior year); no revenue.","Working capital deficit of $21.4M; cash balance $0 at June 30, 2024.","Due to related party (Citius Pharma) $30.9M, up from $19.5M at Sept 30, 2023.","Company expresses substantial doubt about ability to continue as going concern within one year.","Stock-based compensation expense $5.8M for the nine months; $40M in-process R&D asset for LYMPHIR."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-072598","json":"https://secwatch.observer/filing/0001213900-24-072598.json","markdown":"https://secwatch.observer/filing/0001213900-24-072598.md","text":"https://secwatch.observer/filing/0001213900-24-072598.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1851484/000121390024072598/0001213900-24-072598-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1851484/000121390024072598/ea0212260-8ka1_citius.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T07:43:17.056378+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}